The World Health Organization has named antimicrobial resistance, caused by the overuse of antibiotics and other drugs, one of the top 10 public health threats. Less than a century after the discovery of penicillin, physicians are running out of options to treat bacterial infections. In fact, the next global pandemic could be caused by a multidrug resistant strain of a previously eradicated pathogen.

New and sustainable solutions are necessary to get ahead of the trajectory of antimicrobial resistance. However, it is possible to build a better understanding of the antimicrobial crisis and strengthen public health defenses. Clinical research has a key role to play in developing the needed solutions to this rising threat and improving existing healthcare tools.

Register for the webinar to learn about the antimicrobial resistance crisis and what the biopharma and healthcare industries can do to mitigate the impact of future pandemics. Experts from ICON will discuss:

Factors contributing to the rise of antimicrobial resistance, including climate change and industrial farming
Why innovation and improvement in diagnostics, preventative measures and novel treatments is crucial
The current regulatory landscape and how industry has responded
Considerations for a successful infectious disease clinical trial, including lessons learned from the race for a COVID-19 vaccine
Opportunities for the post-antibiotic era

Keywords:

Speakers

Shelley McLendon, Vice President, Vaccines and Infectious Disease, ICON

Shelley has more than 25 years of clinical research experience, 19 of which are tenured at ICON. Shelley provides executive leadership and oversight for ICON’s clinical and project management teams in the implementation and execution of vaccine and infectious disease clinical development programs. She also consults with small to mid-size biotechnology clients and large pharmaceutical companies providing strategic operational guidance and driving partnership development. Shelley is a key leader of ICON’s COVID-19 Taskforce which is cross-functional team of ICON executive leaders whose mission is to make a difference by advancing research in the fight against COVID-19.

Message Presenter

Dr. Caroline Forkin, Vice President, Clinical Research Services, ICON GPHS

Dr. Forkin brings 26 years’ experience in clinical, pharmaceutical and global health settings, including extensive experience in Africa. With a clinical background in Infectious Diseases, Caroline’s experience in Africa included senior roles as HIV/AIDS Advisor for both the World Bank and the Irish Government. These roles involved working with the Mozambican Ministry of Health, National AIDS Council, together with other global health entities such as the Clinton Foundation HIV/AIDS Initiative, the Global Fund for AIDS, TB, and Malaria, the President’s Emergency Plan for AIDS Relief. Dr. Forkin’s pharma experience prior to joining ICON includes country medical lead for two biotech companies. Her role at ICON is Vice President for Clinical Research Services with responsibility for all our studies in Africa and the Middle East.

Message Presenter

Dr. Kersten Kurt Koelsch, MD, Senior Medical Director, Medical Affairs, ICON

Kersten is a board certified internist and infectious diseases specialist with over 15 years of clinical practice and clinical research practice at University Medical Centers in Germany, the US and Australia. He has been involved in numerous Phase I – Phase III studies for antimicrobials, antivirals and vaccines resulting in many international, peer reviewed publications. Kersten has joined ICON over 4 years ago where he is currently appointed as a

Senior Medical Director and leads the medical team dedicated to infectious diseases clinical trials for the Europe and Asia-Pacific region.

Message Presenter

Neddie Zaideikis, MD, MBA, Senior Medical Director, Medical Affairs, ICON

Dr. Neddie Zadeikis is an internist and infectious disease specialist who after 5 years of clinical practice of infectious disease transitioned into industry. She has worked more than 20 years in both the role of medical director at medium-large pharmaceutical companies as well as medical director at contract research organizations in the field of infectious disease. Dr. Zadeikis had been at PRA/ICON for the past 2.5 years and is currently a Senior Medical Director in Infectious Disease.

Message Presenter

Who Should Attend?

This program will be beneficial for:

Pharma project management, especially infectious diseases
Clinical and scientific researchers
Academic institutions and international bodies
Government bodies

What You Will Learn

In this webinar, participants will learn about:

Factors contributing to the rise of antimicrobial resistance, including climate change and industrial farming
Why innovation and improvement in diagnostics, preventative measures and novel treatments is crucial
The current regulatory landscape and how industry has responded
Considerations for a successful infectious disease clinical trial, including lessons learned from the race for a COVID-19 vaccine
Opportunities for the post-antibiotic era

Xtalks Partner

ICON

ICON plc is a world-leading healthcare intelligence and clinical research organisation. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in Dublin, Ireland, ICON will operate from 150 locations in 47 countries and have approximately 38,000 employees as of July 1, 2021.